Site search
2863 results for '' found
How_to_get_to_Area_U_-_549_St_Kilda_Road_-_Map_v3.pdf
Making_the_Move_to_549_St_Kilda_Road_-_Flyer_v4.pdf
A Phase 3, Multicenter, randomised, double-blind, placebo controlled trial to evaluate the efficacy and safety of Navenibart in participants with Hereditary Angioedema (NCT06842823)
A Phase 3, Multicenter, randomised, double-blind, placebo controlled trial to evaluate the efficacy and safety of Navenibart in participants with Hereditary Angioedema (NCT06842823)
/
A Phase I/II, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose and pharmacokinetics of BNT326 as monotherapy and in combination with cancer immunotherapies in pa
A Phase I/II, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose and pharmacokinetics of BNT326 as monotherapy and in combination with cancer immunotherapies in pa
/
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-002 in Participants with Von Willebrand Disease (NCT06754852)
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-002 in Participants with Von Willebrand Disease (NCT06754852)
/
A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy [Bemdaneprocel] for Patients with Parkinsons Disease [PD] (NCT06944522)
A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy [Bemdaneprocel] for Patients with Parkinsons Disease [PD] (NCT06944522)
/
Relapsed or Refractory Multiple Myeloma: Dose Escalation and Expansion of Etentamig in Combination with a CELMoD agent (NCT06896916)
Relapsed or Refractory Multiple Myeloma: Dose Escalation and Expansion of Etentamig in Combination with a CELMoD agent (NCT06896916)
/
A Phase IIb, open label, sequential cohort study comparing KappaMab alone to KappaMab in combination with lenalidomide and low dose dexamethasone [MRd] in Relapsed Refractory Multiple Myeloma (AC
A Phase IIb, open label, sequential cohort study comparing KappaMab alone to KappaMab in combination with lenalidomide and low dose dexamethasone [MRd] in Relapsed Refractory Multiple Myeloma (AC
/
A Phase 2a, Two-Part, Open-Label and Randomized Study to Evaluate the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Patients with Moderately to Severely Active Ulcerati
A Phase 2a, Two-Part, Open-Label and Randomized Study to Evaluate the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Patients with Moderately to Severely Active Ulcerati
/